Bruton's Tyrosine Kinase (BTK) Inhibitor
Ibrutinib for Chronic Graft-versus-Host Disease
This trial is testing ibrutinib, a pill that blocks a protein causing harmful immune reactions, in adults with newly diagnosed moderate or severe chronic graft-versus-host disease (cGVHD). The goal is to see if this drug can help control the disease by reducing the immune system's attack on the body. Ibrutinib was the first agent approved by the U.S. Food and Drug Administration for the treatment of chronic graft-versus-host disease (cGVHD) after failure of one or more lines of systemic therapy.
Popular Filters
Trials for GVHD Patients
JAK2/IRAK1/CSF1R Inhibitor
Pacritinib for Chronic Graft-versus-Host Disease
This trial tests pacritinib, a capsule taken by mouth, in adults with moderate or severe chronic graft-versus-host disease (cGVHD) that hasn't responded to other treatments. Pacritinib helps by blocking proteins that cause inflammation and immune issues. Participants will take the drug regularly and have periodic check-ups over an extended period.
Extended Ibrutinib Treatment for Non-Hodgkin's Lymphoma
This trial provides continued access to ibrutinib for patients who benefited from previous studies and cannot buy it locally. Ibrutinib is an oral medication that stops cancer cells from growing by blocking a protein they need. It is used in the treatment of chronic lymphocytic leukemia and has been studied for its effectiveness in relapsed CLL and as frontline therapy.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
This trial tests if using low dose radiation and certain drugs can help patients with beta-thalassemia or sickle cell disease better accept donor stem cells. The treatment aims to suppress the immune system to reduce rejection of the new cells.
Trials for Graft-versus-Host Disease Patients
JAK2/IRAK1/CSF1R Inhibitor
Pacritinib for Chronic Graft-versus-Host Disease
This trial tests pacritinib, a capsule taken by mouth, in adults with moderate or severe chronic graft-versus-host disease (cGVHD) that hasn't responded to other treatments. Pacritinib helps by blocking proteins that cause inflammation and immune issues. Participants will take the drug regularly and have periodic check-ups over an extended period.
Extended Ibrutinib Treatment for Non-Hodgkin's Lymphoma
This trial provides continued access to ibrutinib for patients who benefited from previous studies and cannot buy it locally. Ibrutinib is an oral medication that stops cancer cells from growing by blocking a protein they need. It is used in the treatment of chronic lymphocytic leukemia and has been studied for its effectiveness in relapsed CLL and as frontline therapy.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
Janus Kinase (JAK) Inhibitor
Ruxolitinib + Panobinostat for Myelofibrosis
This trial is looking at the safety of long-term treatment with ruxolitinib alone or in combination with panobinostat in patients who have previously participated in a study sponsored by Novart
Immunosuppressive Agent
Nonmyeloablative Stem Cell Transplant for Sickle Cell Anemia and Thalassemia
This trial tests if using low dose radiation and certain drugs can help patients with beta-thalassemia or sickle cell disease better accept donor stem cells. The treatment aims to suppress the immune system to reduce rejection of the new cells.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Trials for HLA Positive Patients
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Immunomodulator
Extended vs Short-Term Abatacept Dosing for Graft-versus-Host Disease
This trial is testing whether an extended dosing regimen of abatacept, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will improve outcomes in patients who have received transplants from 7 of 8 HLA matched donors.
Trials for HLA-A Positive Patients
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Chemotherapy
Treg-Enriched Stem Cell Transplant for Leukemia
This trial is studying a new way to give a haploidentical stem cell transplant (using donor cells that have been enriched with regulatory T cells) to people with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome.
Immunomodulator
Extended vs Short-Term Abatacept Dosing for Graft-versus-Host Disease
This trial is testing whether an extended dosing regimen of abatacept, when added to standard calcineurin inhibitor + methotrexate-based prophylaxis, will improve outcomes in patients who have received transplants from 7 of 8 HLA matched donors.
Phase 3 Trials
Probiotic
Probiotics for Preventing Graft-versus-Host Disease
This trial is testing whether Lactobacillus plantarum, a beneficial bacteria found in foods like yogurt, can prevent a serious gut complication called acute graft versus host disease in young patients receiving stem cell transplants. The bacteria may help by keeping the gut healthy and reducing inflammation. Lactobacillus plantarum has been used in human studies to promote beneficial effects in the immune system, alleviate intestinal disorders, and reduce the risk of cardiovascular disease. The study will compare patients taking Lactobacillus plantarum to those not taking it.
Kinase Inhibitor
Long-term Ibrutinib for Lymphoma
This trial aims to provide ongoing access to ibrutinib for patients who have benefited from it in previous studies. Ibrutinib is an oral medication that blocks a protein involved in cancer growth, helping to slow or stop the disease. The study will monitor safety and effectiveness over time. Ibrutinib has been studied extensively and is used to treat various B cell malignancies, including chronic lymphocytic leukemia and mantle cell lymphoma.
Monoclonal Antibodies
Itolizumab + Corticosteroids for Acute Graft-Versus-Host Disease
This trial is testing itolizumab, an IV medication, in patients with severe aGVHD. It aims to see if itolizumab can better control the immune system and reduce inflammation. Itolizumab has been used in various conditions including psoriasis, rheumatoid arthritis, and COVID-19.
Corticosteroid
Belumosudil + Corticosteroids for Chronic Graft Versus Host Disease
This trial is testing a new treatment for people with moderate or severe chronic GVHD. It targets newly diagnosed patients who may not respond well to existing treatments. The goal is to manage or reduce the symptoms of chronic GVHD.
Monoclonal Antibodies
Axatilimab + Corticosteroids for Chronic Graft-Versus-Host Disease
This trial will compare how well a new drug, axatilimab, works with corticosteroids compared to a placebo with corticosteroids in treating moderate or severe chronic graft-versus
Trials With No Placebo
JAK2/IRAK1/CSF1R Inhibitor
Pacritinib for Chronic Graft-versus-Host Disease
This trial tests pacritinib, a capsule taken by mouth, in adults with moderate or severe chronic graft-versus-host disease (cGVHD) that hasn't responded to other treatments. Pacritinib helps by blocking proteins that cause inflammation and immune issues. Participants will take the drug regularly and have periodic check-ups over an extended period.
Monoclonal Antibodies
Tocilizumab for Graft-versus-Host Disease Prevention
This trial is testing whether the addition of the drug tocilizumab to the standard approach for GVHD prevention can reduce the risk of developing GVHD and GVHD-related complications. Tocilizumab works by blocking the effect of Interleukin-6, a protein that is elevated in the blood during periods of inflammation. This could potentially decrease the risk of developing GVHD and GVHD-associated complications.
Extended Ibrutinib Treatment for Non-Hodgkin's Lymphoma
This trial provides continued access to ibrutinib for patients who benefited from previous studies and cannot buy it locally. Ibrutinib is an oral medication that stops cancer cells from growing by blocking a protein they need. It is used in the treatment of chronic lymphocytic leukemia and has been studied for its effectiveness in relapsed CLL and as frontline therapy.
Stem Cell Transplant + Chemotherapy for Leukemia and Lymphoma
This trial is studying how well chemotherapy, total body irradiation, and post-transplant cyclophosphamide work in reducing rates of graft versus host disease in patients with hematologic malignancies undergoing a donor stem cell transplant.
View More Related Trials
Frequently Asked Questions
Introduction to graft vs host disease
What are the top hospitals conducting graft vs host disease research?
When it comes to cutting-edge clinical trials in the complex realm of graft vs host disease (GVHD), several hospitals are leading the way. In Boston, both Dana-Farber Cancer Institute and Massachusetts General Hospital have dedicated themselves to understanding and treating this challenging condition. Dana Farber currently has nine active GVHD trials underway, building upon their impressive history of 23 completed studies since their inaugural trial in 2001. Not far behind is Dana-Farber Cancer Institute with eight ongoing GVHD trials and a significant track record of 35 previous investigations, dating back to 2000. Meanwhile, over at Massachusetts General Hospital, researchers are actively engaged in eight GVHD trials while having conducted an admirable total of 29 such studies since recording their first trial in 2001.
Venturing outside the city limits, we find another prominent institution making strides in the field - The National Institutes of Health Clinical Center located in Bethesda. This renowned center currently has seven active clinical trials focused on GVHD and boasts a respectable history of fourteen previously conducted investigations that date all the way back to 1996 when they recorded their initial study on this subject.
Lastly but certainly not least, we turn our attention towards the West Coast where Fred Hutchinson Cancer Research Center stands as a beacon for innovation and progress against GVHD. Situated amidst Seattle's vibrant medical community, this prestigious research center currently features seven active clinical trials tackling graft vs host disease head-on while contributing significantly through an astonishing fifty-one completed studies since recording its first ground-breaking trial back in1986.
These hospitals' unwavering commitment to unraveling the complexities surrounding graft vs host disease demonstrates how dedication and collaboration fuel scientific advancement. Through these pioneering efforts carried out across various locations nationwide , hope continues to grow for patients affected by this challenging condition as breakthroughs inch closer within reach
Which are the best cities for graft vs host disease clinical trials?
When it comes to graft vs host disease clinical trials, several cities emerge as prominent hubs for research and development. Boston, Massachusetts leads the way with 41 active trials investigating treatments like Abatacept, Interleukin-2, and Cohort A: Belumosudil + Standard of Care Medications. New york City follows closely behind with 23 ongoing studies exploring therapies such as Ibrutinib, Alpha-1 antitrypsin (AAT), and GDC-8264. Duarte, California also plays a significant role in this field with 21 active trials focusing on Ibrutinib, Belumosudil (KD025), Axatilimab among other interventions. Additionally, Seattle, Washington and Atlanta Georgia have notable contributions to graft vs host disease clinical trials with 16 and 15 active studies respectively researching innovative treatments like Alpha-1 antitrypsin (AAT) and Abatacept. These cities offer individuals affected by graft vs host disease access to cutting-edge clinical trials that pave the way for better care options and improved patient outcomes.
Which are the top treatments for graft vs host disease being explored in clinical trials?
Graft vs host disease, a complex condition, is the focus of extensive research in ongoing clinical trials. Among the top treatments being explored are:
- Ibrutinib: Showcasing its potential with five active trials and nine all-time graft vs host disease studies since 2013.
- Abatacept: Proving its worth in three ongoing trials and seven previous graft vs host disease investigations which began in 2013.
- Cyclophosphamide: Demonstrating promise through three active and 30 all-time graft vs host disease trials dating back to 2007.
- Ruxolitinib: Making strides with three active and a total of fourteen past graft vs host disease studies initiated from 2016 onwards.
These innovative treatment options hold immense hope for patients battling this challenging disorder.
What are the most recent clinical trials for graft vs host disease?
Exciting advancements are underway in the realm of graft vs host disease, with recent clinical trials offering hope for improved treatment strategies. One notable trial focuses on CD34+ Peripheral Blood Progenitor Cell (PBSC) Transplant combined with a Busulfan/Melphalan/Fludarabine Regimen. This Phase 2 study brings potential benefits to individuals grappling with graft vs host disease by exploring novel transplantation methods. Another trial investigates prophylaxis techniques specifically tailored to mitigate the risk of graft vs host disease development, showing promise as a preventive measure. Additionally, steroid therapy and corticosteroid treatments have emerged as candidates for managing graft vs host disease symptoms based on encouraging results from Phase 1 and Phase 2 trials. With these innovative approaches emerging, there is renewed optimism for better outcomes in the battle against graft vs host disease.
What graft vs host disease clinical trials were recently completed?
Recent completion of numerous clinical trials for graft vs host disease brings hope and progress in the battle against this challenging condition. Notable studies include a December 2020 trial sponsored by the University of California, San Francisco, focusing on dexamethasone 0.5mg/5ml solution in Mucoloxâ„¢. Genentech, Inc., completed their Efmarodocokin Alfa trial in November 2020. Further advancements were made with Washington University School of Medicine's Baricitinib trial concluding in April 2020 and Regimmune Corporation's RGI-2001 study finishing in November 2019. These milestones underline ongoing efforts to enhance treatment options for patients grappling with graft vs host disease.